Eur Thyroid News Today : Breaking News, Live Updates & Top S

Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease

Published: May 21, 2024

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com

Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA

Published: February 20, 2024

ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company

Source: thailand-business-news.com

Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

Published: May 8, 2023

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Source: prnewswire.com

Ipsen: ASCO 2022: New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer

Published: May 26, 2022

COSMIC-021 Phase Ib study is evaluating Cabometyx (cabozantinib) in combination with atezolizumab in advanced solid tumors, including non-small cell lung cancer New analyses from pivotal Phase

Source: finanznachrichten.de

Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

Published: May 11, 2022

-- Nationwide campaign spotlights mental health impact of living with TED -- For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (Nasdaq: HZNP) is partnering